Volume 33, Issue 11 (February 2023)                   Studies in Medical Sciences 2023, 33(11): 786-795 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zaboli Mahdiabadi M, Abbasi Dolatabadi Z, Nemati Dopolani F, Razavinasab S A, Ivanbagha R, Zeid Abadinejad M R, et al . CLINICAL EFFECTIVENESS OF REGDANVIMAB IN THE TREATMENT OF PATIENTS WITH COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS. Studies in Medical Sciences 2023; 33 (11) :786-795
URL: http://umj.umsu.ac.ir/article-1-5916-en.html
Assistant Professor of Medical Virology, Department of Microbiology, Parasitology and Immunology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran (First Corresponding Author) , Chkarami.chiman@gmail.com
Abstract:   (800 Views)
Background & Aims: Regdanumab is a monoclonal antibody that is widely used to treat the patients with COVID-19. The aim of this study was to investigate the clinical effectiveness of Regdanumab in the patients with COVID-19.
Materials & Methods: A systematic review of the most important major databases including; PubMed, Cochrane Library, Scopus and Web of Science were conducted up to August 2022. Also, a manual search was performed in the sources of primary review and key studies. No restrictions were considered for the language and year of publication of the studies. Evaluation of the quality of studies was performed using the Newcastle checklist. Efficacy outcomes included reduction in mortality, length of hospital stay, disease progression, and need for oxygen therapy. Meta-analysis was performed using Comprehensive Meta-Analysis version 3 software.
Results: Out of 208 articles, seven studies met the inclusion criteria. The results of the meta-analysis showed that the risk ratio (RR) in the Regdanumab group was 0.23 (CI95% 0.05 - 1.02), for the duration of hospitalization was -1.15 (CI95% -0.49 - 1.80), and the need for oxygen therapy was 0.43 (CI95% 0.34-0.56). However, no significant effect was observed for the outcomes of mortality rate, mechanical ventilation and clinical improvement (P˃0.05).
Conclusion: The results of the meta-analysis showed that Regdanumab reduces mortality and length of hospitalization in the patients with COVID-19; although it had no effect on reducing the need for mechanical ventilation and clinical improvement in patients.
Full-Text [PDF 744 kb]   (440 Downloads)    
Type of Study: Review article | Subject: عفونی

References
1. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020;34: 101623. [DOI:10.1016/j.tmaid.2020.101623] [PMID] [PMCID]
2. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 2020;12(4): 372. [DOI:10.3390/v12040372] [PMID] [PMCID]
3. Jean S-S, Lee P-I, Hsueh P-R. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect 2020;53(3): 436-43. [DOI:10.1016/j.jmii.2020.03.034] [PMID] [PMCID]
4. Amani B, Zareei S, Amani B, Zareei M, Zareei N, Shabestan R, et al. Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence. Immun Inflamm Dis 2022;10(6): e628. [DOI:10.1002/iid3.628]
5. Delang L, Neyts J. Medical treatment options for COVID-19. Eur. Heart J. Acute Cardiovasc. Care 2020;9(3): 209-14. [DOI:10.1177/2048872620922790] [PMID] [PMCID]
6. Coopersmith CM, Antonelli M, Bauer SR, Deutschman CS, Evans LE, Ferrer R, et al. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Crit Care Med 2021;49(4): 598-622. [DOI:10.1097/CCM.0000000000004895] [PMID]
7. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Statpearls [internet] 2022. [Google Scholar]
8. Amani B, Zareei S, Amani B. Rapid review and meta‐analysis of adverse events associated with molnupiravir in patients with COVID-19. Br J Clin Pharmacol 2022;88(10): 4403-11. [DOI:10.1111/bcp.15449] [PMID] [PMCID]
9. Singh S, Tank NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, et al. Monoclonal antibodies: a review. Curr Clin Pharmacol 2018;13(2): 85-99. [DOI:10.2174/1574884712666170809124728] [PMID]
10. Lu M, Brashear HR. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous bapineuzumab: a single‐ascending‐dose study in patients with mild to moderate Alzheimer disease. Clin Pharmacol Drug Dev 2019;8(3): 326-35. [DOI:10.1002/cpdd.584] [PMID]
11. Greenwald M, Szczepanski L, Kennedy A, Veenhuizen M, Komocsar WJ, Polasek E, et al. A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis. Arthritis Res Ther 2014;16(4): 1-10. [DOI:10.1186/s13075-014-0415-2] [PMID] [PMCID]
12. Xue T, Yang Y, Lu Q, Gao B, Chen Z, Wang Z. Efficacy and safety of monoclonal antibody therapy in neuromyelitis optica spectrum disorders: evidence from randomized controlled trials. Mult Scler Relat Disord 2020;43: 102166. [DOI:10.1016/j.msard.2020.102166] [PMID]
13. Welman A, Outhoff K. Evidence of the Clinical Efficacy of Antiviral Agents against SARS-CoV-2. Int J Pharm Pharm Sci 2021: 94-111. [DOI:10.51847/E3AXGWu0IP]
14. Bansal V, Mahapure KS, Bhurwal A, Gupta I, Hassanain S, Makadia J, et al. Mortality benefit of remdesivir in COVID-19: a systematic review and meta-analysis. Front Med 2021: 1124. [DOI:10.3389/fmed.2020.606429] [PMID] [PMCID]
15. Elsawah HK, Elsokary MA, Abdallah MS, ElShafie AH. Efficacy and safety of remdesivir in hospitalized Covid‐19 patients: systematic review and meta‐analysis including network meta‐analysis. Rev Med Virol 2021;31(4): e2187. Available from: http: //dx.doi.org/10.1002/rmv.2187 [DOI:10.1002/rmv.2187] [PMID]
16. Kaka AS, MacDonald R, Greer N, Vela K, Duan-Porter W, Obley A, et al. Major update: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians Practice Points. Ann Intern Med 2021;174(5): 663-72. [DOI:10.7326/M20-8148] [PMID] [PMCID]
17. Okoli GN, Rabbani R, Copstein L, Al-Juboori A, Askin N, Abou-Setta AM. Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Infect Dis 2021: 1-9. [DOI:10.1080/23744235.2021.1923799] [PMID] [PMCID]
18. Kim T, Joo D-H, Lee SW, Lee J, Lee SJ, Kang J. Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19. J Clin Med 2022;11(5): 1412. [DOI:10.3390/jcm11051412] [PMID] [PMCID]
19. Hong SI, Ryu B-H, Hong K-W, Bae I-G, Cho O-H. Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea. Infect Chemother 2022;54(1): 114. [DOI:10.3947/ic.2021.0143] [PMID] [PMCID]
20. Lee JY, Lee JY, Ko J-H, Hyun M, Kim HA, Cho S, et al. Effectiveness of regdanvimab treatment in high-risk COVID-19 patients to prevent progression to severe disease. Front Immunol 2021: 4998. [DOI:10.3389/fimmu.2021.772320] [PMID] [PMCID]
21. Streinu-Cercel A, Săndulescu O, Preotescu L-L, Kim JY, Kim Y-S, Cheon S, et al., editors. Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients with Mild-to-Moderate Coronavirus Disease 2019. Open forum infectious diseases; 2022: Oxford University Press US. [DOI:10.1093/ofid/ofac053] [PMID] [PMCID]
22. Stevens A, Garritty C, Hersi M, Moher D. Developing PRISMA-RR, a reporting guideline for rapid reviews of primary studies (Protocol). Equator Network 2018. [Google Scholar]
23. Choi SJ, Park S-W, Lee E. Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study. Infect Chemother 2022;54(1): 91. [DOI:10.3947/ic.2021.0140] [PMID] [PMCID]
24. Jang YR, Oh YJ, Kim JY. Clinical Effectiveness of Regdanvimab Treatment for Mild to Moderate COVID-19: A Retrospective Cohort Study. Curr Ther Res 2022: 100675. [DOI:10.1016/j.curtheres.2022.100675] [PMID] [PMCID]
25. Lee S, Lee SO, Lee JE, Kim K-H, Lee SH, Hwang S, et al. Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study. Int Immunopharmacol 2022;106: 108570. [DOI:10.1016/j.intimp.2022.108570] [PMID] [PMCID]
26. Park S, Je NK, Kim DW, Park M, Heo J. Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study. J Korean Med Sci 2022;37(13): e102. [DOI:10.3346/jkms.2022.37.e102] [PMID] [PMCID]
27. Amani B, Amani B. Efficacy and safety of regdanvimab in patients with mild to moderate COVID‐19: A rapid review and meta‐analysis. Br J Clin Pharmacol 2023. [DOI:10.1002/rmv.2402] [PMID] [PMCID]
28. Yang M, Li A, Jiang L, Wang Y, Tran C, Ao G. Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis. J Infect 2022;85(4): e122-e4. [DOI:10.1016/j.jinf.2022.05.044] [PMID] [PMCID]
29. Lin WT, Hung SH, Lai CC, Wang CY, Chen CH. The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: A systematic review and meta‐analysis of randomized controlled trials. J Med Virol 2022;94(5): 2222-9. [DOI:10.1002/jmv.27623] [PMID] [PMCID]
30. Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med 2022;54(1): 516-23. [DOI:10.1080/07853890.2022.2034936] [PMID] [PMCID]
31. Amani B, Amani B. Efficacy and safety of sotrovimab in patients with COVID‐19: A rapid review and meta‐analysis. Rev Med Virol 2022;32(6): e2402. [DOI:10.1002/rmv.2402] [PMID] [PMCID]
32. Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: a rapid review and meta‐analysis. J Med Virol 2022. [DOI:10.1002/rmv.2402] [PMID] [PMCID]
33. Niknam Z, Jafari A, Golchin A, Danesh Pouya F, Nemati M, Rezaei-Tavirani M, et al. Potential therapeutic options for COVID-19: an update on current evidence. Eur J Pharm Med Res 2022;27(1): 1-15. [DOI:10.1186/s40001-021-00626-3] [PMID] [PMCID]
34. Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1. 617.2 (Delta) surge. J Clin Virol 2021;145: 105026. [DOI:10.1016/j.jcv.2021.105026] [PMID] [PMCID]
35. Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb RL, Chen P, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med 2021;385(15): 1382-92. [DOI:10.1056/NEJMoa2102685] [PMID] [PMCID]
36. Razonable RR, Pawlowski C, O'Horo JC, Arndt LL, Arndt R, Bierle DM, et al. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. Clin Med 2021;40: 101102. https://doi.org/10.2139/ssrn.3854566 [DOI:10.1016/j.eclinm.2021.101102]
37. Saheb Sharif‐Askari F, Ali Hussain Alsayed H, Tleyjeh I, Saheb Sharif‐Askari N, Al Sayed Hussain A, Saddik B, et al. Sotrovimab Lowers the Risk of COVID‐19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates. Clin Pharmacol Ther 2022. [DOI:10.1002/cpt.2700] [PMID] [PMCID]
38. Koehler J, Ritzer B, Weidlich S, Gebhardt F, Kirchhoff C, Gempt J, et al. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany. Infection 2021;49(6): 1313-8. [DOI:10.1007/s15010-021-01657-y] [PMID] [PMCID]
39. Aggarwal N, Beatty L, Bennett TD, Carlson N, Davis C, Kwan B, et al. Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. medRxiv 2022. [DOI:10.1101/2022.04.03.22273360]
40. Xiang Hr, He B, Li Y, Cheng X, Zhang Qz, Peng Wx. Bamlanivimab plus etesevimab treatment have a better outcome against COVID‐19: A meta‐analysis. J Med Virol 2022;94(5): 1893-905. [DOI:10.1002/jmv.27542] [PMID]
41. Miyashita N, Nakamori Y, Ogata M, Fukuda N, Yamura A, Ishiura Y. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant. J Infect Chemother 2022. [DOI:10.1016/j.jiac.2022.05.012] [PMID] [PMCID]
42. Falcone M, Tiseo G, Valoriani B, Barbieri C, Occhineri S, Mazzetti P, et al. Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe COVID-19 and role of variants of concern. Infect Dis Ther 2021;10(4): 2479-88. [DOI:10.1007/s40121-021-00525-4] [PMID] [PMCID]
43. Wynia MK, Beaty LE, Bennett TD, Carlson NE, Davis CB, Kwan BM, et al. Real world evidence of neutralizing monoclonal antibodies for preventing hospitalization and mortality in COVID-19 outpatients. medRxiv 2022. [DOI:10.1016/j.chest.2022.10.020] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb